Up a level |
Frankiewicz, Andrzej ORCID: 0000-0001-8826-7030, Peczynski, Christophe ORCID: 0000-0002-3829-0088, Giebel, Sebastian ORCID: 0000-0002-4827-4401, Harrington, Alenca, Socie, Gerard, Niederwieser, Dietger, Scheid, Christoph, Bornhaeuser, Martin, Kroeger, Nicolaus, Elmaagacli, Ahmet, Afanasyev, Boris, Dreger, Peter, Roessig, Claudia, Blaise, Didier, Kratz, Christian, Yakoub-Agha, Ibrahim, Kremens, Bernhard, Niemeyer, Charlotte Marie, Wulf, Gerald, Blau, Igor, Penack, Olaf, Greinix, Hildegard and Basak, Grzegorz W. (2020). Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. Front. Immunol., 11. LAUSANNE: FRONTIERS MEDIA SA. ISSN 1664-3224
Goldschmidt, Hartmut, Mai, Elias K., Duerig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Huegle-Doerr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Haenel, Mathias and Salwender, Hans J. (2020). Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 34 (7). S. 1853 - 1866. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klein, Eva-Maria, Tichy, Diana, Salwender, Hans J., Mai, Elias K., Duerig, Jan, Weisel, Katja C., Benner, Axel, Bertsch, Uta, Akhavanpoor, Mabast, Besemer, Britta, Munder, Markus, Lindemann, Hans-Walter, Hose, Dirk, Seckinger, Anja, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 13 (19). BASEL: MDPI. ISSN 2072-6694
Mai, Elias K., Miah, Kaya, Bertsch, Uta, Duerig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Benner, Axel, Salwender, Hans J. and Goldschmidt, Hartmut . Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 35 (10). S. 3007 - 3012. LONDON: SPRINGERNATURE. ISSN 1476-5551